Previous Close | 43.43 |
Open | 48.00 |
Bid | 47.05 |
Ask | 48.15 |
Strike | 85.00 |
Expire Date | 2025-01-17 |
Day's Range | 48.00 - 48.00 |
Contract Range | N/A |
Volume | |
Open Interest | 123 |
RAHWAY, N.J., May 15, 2024--Merck to Present New Data at 2024 ASCO Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
RAHWAY, N.J., May 13, 2024--Merck Update on KeyVibe-010 Evaluating Coform of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients W/ Resected High-Risk Melanoma